^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Foundation Medicine

    i
    Other names: Foundation Medicine, | Foundation Medicine | Lexent Bio, | Lexent Bio
    Evidence
    News
    3ms
    Circulating tumor DNA (ctDNA) dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial. (ASCO-GU 2026)
    P1/2 | "Early MR (by C2D1) was achieved in 35% of patients and strongly associated with improved rPFS and OS while PSA50 responses by C2D1 were not observed in any patients. The rPFS benefit of adding olaparib to radium-223 appeared more evident in those who achieved a MR. Early on treatment ctDNA dynamics in bone-dominant mCRPC may be a valuable tool for treatment decisions with radium-223 therapy."
    Clinical • P2 data • Circulating tumor DNA
    |
    FoundationOne®Monitor
    |
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)